Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark B Effron

Showing results (81-90 of 91) with videos related to

Pageof 10
Sort By:
JAMA Cardiology|October 4, 2023
Effectiveness and Safety of Enteric-Coated vs Uncoated Aspirin in Patients With Cardiovascular Disease: A Secondary Analysis of the ADAPTABLE Randomized Clinical TrialAmber Sleem, Mark B Effron, Amanda Stebbins, et al.
The New England Journal of Medicine|May 24, 2008
Facilitated PCI in patients with ST-elevation myocardial infarctionStephen G Ellis, Michal Tendera, Mark A de Belder, et al.
American Heart Journal|June 8, 2023
Comparison of the effectiveness and safety of 2 aspirin doses in secondary prevention of cardiovascular outcomes in patients with chronic kidney disease: A subgroup analysis of ADAPTABLEKamal Gupta, Harsh Mehta, Hwasoon Kim, et al.
Contemporary Clinical Trials|July 27, 2025
Association of study visit interval length with follow-up completeness and adherence to assigned study drug dose: A randomized comparison of participants in the ADAPTABLE trialDennis I Narcisse, Jeff Whittle, Grace M Rhodes, et al.
American Heart Journal|March 5, 2013
TransRadial Education and Therapeutics (TREAT): shifting the balance of safety and efficacy of antithrombotic agents in percutaneous coronary intervention: a report from the Cardiac Safety Research ConsortiumConnie N Hess, Sunil V Rao, David F Kong, et al.
Journal of the American Heart Association|February 13, 2024
Age and Aspirin Dosing in Secondary Prevention of Atherosclerotic Cardiovascular DiseaseGuillaume Marquis-Gravel, Amanda Stebbins, Lisa M Wruck, et al.
JAMA Cardiology|March 19, 2020
Rationale and Design of the Aspirin Dosing-A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) TrialGuillaume Marquis-Gravel, Matthew T Roe, Holly R Robertson, et al.
Journal of the American Geriatrics Society|April 21, 2023
Pragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): Trial design and rationaleJacob Joseph, Nicholas M Pajewski, Rowena J Dolor, et al.
The New England Journal of Medicine|May 17, 2021
Comparative Effectiveness of Aspirin Dosing in Cardiovascular DiseaseW Schuyler Jones, Hillary Mulder, Lisa M Wruck, et al.
The New England Journal of Medicine|August 5, 2021
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19, , , et al.
Pageof 10

Showing results (81-90 of 91) with videos related to

Sort By:
Pageof 10
JAMA Cardiology|October 4, 2023
Effectiveness and Safety of Enteric-Coated vs Uncoated Aspirin in Patients With Cardiovascular Disease: A Secondary Analysis of the ADAPTABLE Randomized Clinical TrialAmber Sleem, Mark B Effron, Amanda Stebbins, et al.
The New England Journal of Medicine|May 24, 2008
Facilitated PCI in patients with ST-elevation myocardial infarctionStephen G Ellis, Michal Tendera, Mark A de Belder, et al.
American Heart Journal|June 8, 2023
Comparison of the effectiveness and safety of 2 aspirin doses in secondary prevention of cardiovascular outcomes in patients with chronic kidney disease: A subgroup analysis of ADAPTABLEKamal Gupta, Harsh Mehta, Hwasoon Kim, et al.
Contemporary Clinical Trials|July 27, 2025
Association of study visit interval length with follow-up completeness and adherence to assigned study drug dose: A randomized comparison of participants in the ADAPTABLE trialDennis I Narcisse, Jeff Whittle, Grace M Rhodes, et al.
American Heart Journal|March 5, 2013
TransRadial Education and Therapeutics (TREAT): shifting the balance of safety and efficacy of antithrombotic agents in percutaneous coronary intervention: a report from the Cardiac Safety Research ConsortiumConnie N Hess, Sunil V Rao, David F Kong, et al.
Journal of the American Heart Association|February 13, 2024
Age and Aspirin Dosing in Secondary Prevention of Atherosclerotic Cardiovascular DiseaseGuillaume Marquis-Gravel, Amanda Stebbins, Lisa M Wruck, et al.
JAMA Cardiology|March 19, 2020
Rationale and Design of the Aspirin Dosing-A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) TrialGuillaume Marquis-Gravel, Matthew T Roe, Holly R Robertson, et al.
Journal of the American Geriatrics Society|April 21, 2023
Pragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): Trial design and rationaleJacob Joseph, Nicholas M Pajewski, Rowena J Dolor, et al.
The New England Journal of Medicine|May 17, 2021
Comparative Effectiveness of Aspirin Dosing in Cardiovascular DiseaseW Schuyler Jones, Hillary Mulder, Lisa M Wruck, et al.
The New England Journal of Medicine|August 5, 2021
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19, , , et al.
Pageof 10